IMPACT® ACS
IMPACT® ACS is an autologous conditioned serum that alleviates chronic inflammation and effectively reduces joint pain.
2,100+ annual applications in Austria
Effective inflammation and pain relief
Reduces inflammation & pain through increased levels of anti-inflammatory cytokines.
Lasting impact
The body's own protective proteins have a long-term anti-inflammatory and regenerative effect.
Efficient production
The fully automated process saves time and effort in clinical practice.
IMPACT® ACS Indications
Osteoarthritis
- in particular activated osteoarthritis, e.g. in knee joints
Degenerative spine diseases
- spondylarthrosis
- osteochondrosis
- spondylosis
- degenerative spinal stenosis
Nerve compression syndrome
- intervertebral disc protrusion
- intervertebral disc prolapse
- degenerative neuroforamen stenosis
Back pain
Tendon and muscle injuries
Arthrosis and inflammatory processes
Degenerative and inflammatory joint diseases such as osteoarthritis cause increased release of inflammatory cytokines, which damage cartilage. Cytokines such as TNF, IL-1B, and IL-17 play a key role in inflammation and cartilage degradation. In osteoarthritis patients, an oversupply of these cytokines leads to an imbalance.
Cytokine imbalance: IMPACT® ACS balances
IMPACT® ACS helps to curb the chronic inflammatory response in the joint at an early stage. The autologous conditioned serum (ACS) stimulates the production of anti-inflammatory cytokines and is enriched with growth factors. This serum is injected into the affected joints and has anti-inflammatory, analgesic and cartilage protection effects.
The aim of ACS therapy: to increase the body's own protective proteins
In IMPACT ACS therapy, venous whole blood is taken from the patient. Special glass beads stimulate the production of anti-inflammatory cytokines. After centrifugation, a cell-free serum is produced, which is injected directly into the affected joint. The increased protective proteins displace the pro-inflammatory cytokines and inhibit the inflammatory process.
Detection of exosomes in IMPACT® ACS
The presence of exosomes in ACS was confirmed by a study in Austria at the Center for Regenerative Medicine at Danube University Krems. The following markers were detected:
CD9+
A common marker on exosomes.
CD63+
It is also a common marker that occurs on the surface of exosomes.
IMPACT® studies
